Member Info for banjomick

Unless I made a mistake AGY have changed their tentative Interim Results date from the 8th to the 7th: 07 03 2018 Interim Results 2018 Announcement (tentative) http://www.allergytherapeutics.com/investor-relations/financial-calendar/ Hmmm, which now ties in with Investor Evening - 7 March - London - Allergy Therapeutics, Bluejay Mining, Healthperm and Mercia Technologies http://www.moneyam.com/InvestorsRoom/posts.php?tid=20764#lastread and te start of the European Drug Safety Summit 2018 http://www.wplgroup.com/aci/event/european-drug-safety-summit/

28 February 2018 Allergy Therapeutics plc Allergy Therapeutics prepares for manufacturing and clinical development of Polyvac� Peanut allergy product - Specialist CMO AGC Biologics engaged - 28 February 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces it has signed a contract with AGC Biologics (Heidelberg, Germany) to scale up the manufacturing of its Polyvac� Peanut product for use in clinical studies. Pre-clinical findings using Polyvac� Peanut demonstrated protection against anaphylaxis and induction of protective immunity. It is planned that further development of this product will enable the Group to address the current unmet need. Allergy Therapeutics will now scale-up and validate the manufacturing processes for Polyvac� Peanut as part of the clinical development programme. Food allergy, and in particular peanut allergy, is a significant and strategically important area for Allergy Therapeutics due to the serious and destabilising effects on the lives of both patients and their families. The global addressable market for therapies to help mitigate these effects is estimated at $8 billion per annum1. AGC Biologics is a contract manufacturing organisation (CMO) specialising in expression and purification of recombinant therapies. The company has produced batches of cGMP-compliant material for a variety of pharmaceutical and biotech companies with proven operational expertise in the transfer, development, scale-up and validation of cGMP processes and has prior experience in expression of virus like particle constructs. Manuel Llobet, CEO at Allergy Therapeutics, stated: "The disruption to patients' social and family life as a result of food allergies is significant, and we are committed to addressing these current unmet needs. The Group's peanut vaccine programme complements our current marketed range of ultra-short course vaccines in terms of safety, efficacy and improved patient convenience. We are pleased to start working with AGC Biologics in order to further progress the clinical programme."

You are right, that article is a report based on the recent "Q4 2017 Operations Update and 2018 Outlook" with nothing new added: http://www.victoriaoilandgas.com/investors/news/q4-2017-operations-update-and-2018-outlook but at the end of the day it's positive publicity for VOG/GDC: https://energies-media.com/gaz-cameroun-pourparlers-dpdc-grenor-elargir-clientele/ https://energies-media.com/vog-projette-vente-100-millions-pieds-cubes-gaz-naturel-jour-ici-2021/

Cameroon gas talks with DPDC and Grenor to expand customer base February 22, 2018 by Energies Media Dibamba Power Development Company (DPDC) and the Norwegian Grenor would consider building thermal power plants to generate electricity from gas in Douala Gas du Cameroun (GDC) could soon supply two independent power producers with natural gas, Energies Media learned via a report released last week by the company. The subsidiary of the British firm Victoria Oil and Gas PLC (VOG) is in talks with Dibamba Power Development Company (DPDC) - a subsidiary of Britain's Globeleq - and the Norwegian group Grenor for the supply of natural gas to them. DPDC has a thermal power station of 88 MW in Yassa (Douala), fueled by heavy fuel oil; and Grenor is working on a 150 MW thermal power station project, still in the Littoral region. This plant will be supplied with natural gas . The potential entry of these independent power producers into GDC's customer portfolio will substantially increase the amount of natural gas distributed by this VOG subsidiary and impact its financial health. Its largest current customer, the concessionaire of the public electricity distribution service, ENEO , has suspended the supplies of its 50 MW power plant since early January 2018 for cash tensions. ENEO supplies accounted for 53% of the sales of the Logbaba gas field - operated by GDC - for the 2017 financial year. Without the resumption of the partnership with ENEO, the company has difficulties in implementing the development plan of its subsidiaries. capabilities. Gaz du Cameroun is the only natural gas distributor in Douala, the economic capital of Cameroon. GDC operates in the Logbaba gas field and has been serving a pipeline since 2012 with the industrial areas of Bassa and Bonab�ri , in addition to ENEO. https://energies-media.com/gaz-cameroun-pourparlers-dpdc-grenor-elargir-clientele/

keith1-As usual "cannot remember a worse time than this" and fails as usual to mention that VOG will pay 57% of drilling costs and not all! naks-Can't read or understand an RNS/announcement oldtimer- Is just senile! 3cardbrag-Linking VOG to 911! bigsmoke-Been out all day so banging in 10 posts for the hell of it! :-)

short term traders trying to cause volatility by scaremongering and pathetic posts.

"What is the insurance claim for, a lightening strike, or Savannah dropping strings into La108?????? What else happened icant remember all the stories s now." Another idiot, try reading (if you can) : "The final cost of the well programme was $87 million against an original budget of $40 million. This overrun was the result of a combination of many factors and a detailed analysis will be completed. However, the well control event during the drilling of La-108 was the main cause of the delay and cost overruns. An insurance claim has been lodged with the Company�s insurers to cover the substantial and material costs associated with this event and the consequential schedule and cost overrun. As is normal in these situations, the outcome of our claim is not certain." http://www.victoriaoilandgas.com/investors/news/q4-2017-operations-update-and-2018-outlook

"we were supposed to pay 40 mill now 87" more lies and scaremongering

Is Ahmet suggesting that he hopes to sign a new contract with ENEO in the next couple of weeks? The Cameroon Government have said not to decommission the Logbaba and Bassa power plants! https://www.youtube.com/watch?time_continue=27&v=eO0ErzcKNHk

It's a pretty common style: https://www.google.co.uk/search?q=oil+and+gas+company+logos&dcr=0&tbm=isch&tbo=u&source=univ&sa=X&ved=0ahUKEwiW9vaVpbLZAhXpJcAKHdYkATIQsAQIKA&biw=1920&bih=1088

lol

He has multiple minds, wow! naks, have you sold-up by any chance? Lots of school boy scaremongering from your keyboard :-)

Q4 2017 Operations Update and 2018 Outlook http://www.victoriaoilandgas.com/investors/news/q4-2017-operations-update-and-2018-outlook Victoria Oil & Gas confident of positive outcome to ENEO issue (Video) https://www.youtube.com/watch?time_continue=3&v=eO0ErzcKNHk and remember: "In practical terms, at the operational level, in the energy sector, the PDI provides for the construction of the maximum number of energy infrastructure on the Sanaga, to pack this river on which is located 75% of the hydroelectric potential of Cameroon. This is also about �speeding up the development of other forms of renewable energy (biomass, natural gas, solar power) to provide affordable and ecological energy to our local industries, and finally concern ourselves with the vast market our big neighbour, Nigeria, represents with energy needs estimated at 88,800 Megawatts in 2020�." http://www.businessincameroon.com/public-management/2501-6839-cameroon-plans-to-b

Get rid of the day traders-lol

usual suspects will be collecting their 50p for a day posting shite again! :-)

you are just a little shit! :-)

I could average down but rather put this one down to experience. Looking very good for anyone buying in now or over last two years.

get some money back after all, average 85p!!!!! gla

Additionally, all the German TAV plans are on track with the recent incorporation of the clinical development programmes for the oral vaccine Oralvac, under a co- development agreement with Ergomed announced in December 2017. Outlook Post the period end current trading remains positive and the Board remains confident in the outlook for the business for the remainder of the year. Allergy Therapeutics' competitive position continues to improve with increased market share, in the countries in which it operates, increasing in line with its long term plans to achieve 20% market share. Market share gains are consistent across its key European markets, notably in highly competitive markets like Spain, Germany, Austria and Holland. Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "Our strategy to prioritise patient friendly vaccines with focus on patient compliance and improving adherence rates is demonstrating success. Our portfolio of ultra-short course vaccines is driving our market penetration in Europe and preparing the ground for a successful US entry. All our key development programmes are being executed according to plan and our long-term strategic objectives, are on track. We feel privileged to keep developing Allergy Therapeutics as we satisfy the significant unmet needs of our patients." http://www.lse.co.uk/share-regulatory-news.asp?shareprice=AGY&ArticleCode=gpw01pwr&ArticleHeadline=Trading_Update

Market share gains driving top line growth Strong cash position sustained by good performance. 31 January 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today provides a trading update for the six months ended 31 December 2017, ahead of its unaudited interim results to be announced on 7 March 2018. Financials The Group reports that it is trading in line with the Board's expectations. Reported revenues for the six months ended 31 December 2017 are expected to be �42.2m (2016: �40.4m), representing 4.4% growth on a reported basis and 1.3% growth at constant currency. The Group has continued to grow in the past six months of 2017, notwithstanding an abnormally weak pollen season in Central Europe1, outperforming the market by an average of 4 percentage points2 thanks to focused sales and marketing strategy and its exclusive technology platform. In Germany, the Group's market share has risen by one percentage point to 14% over the past twelve months on a moving annual average basis. The fastest growing operations for the Group in the six months ended 31 December 2017 were the Spanish subsidiary as well as the Emerging Markets segment. By leveraging additional revenues on current infrastructure, the Group continues to improve its operational margins pre-R&D. This, along with careful planning of working capital and capex investments, has allowed the Group to maintain a strong cash position of �25.8m (31 December 2016: �27.8m). Products There continues to be increasing uptake of the Group's portfolio of convenient and patient-friendly treatments. Pre-seasonal ultrashort course aluminium free vaccine Pollinex Quattro, designed to address the cause of symptoms of patients sensitised to seasonal allergens (grass, trees, ragweed), remains a key growth driver for Allergy Therapeutics based on the benefits of the Group's treatment programs. Venomil, the Group's product that treats the life threatening condition of venom allergy, grew strongly as well as Acarovac Plus3 which continued to outperform the rest of the portfolio in Spain. Pipeline The Group's Phase III PQ Birch trial has recently completed recruitment, with results expected in H2 2018. The successful completion of this pivotal Phase III study would fulfil the requirements for PQ Birch under the Therapieallergene-Verordnung (TAV) of the Paul Ehrlich Institute before anticipated marketing authorisation. The PQ Grass Phase II trial continues to recruit on schedule with results also expected in H2 2018. Following completion of this trial, meetings with the regulatory authorities in the US and Germany will be necessary to enable Phase III trial design.